TNF-blocking drugs and infection; recommendations for daily practice;TNF-blokkerende geneesmiddelen en infecties; adviezen voor de dagelijkse praktijk

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 10, 2007, Pages 588-593

  Jacobs, J W G ^a   Creemers, M C W ^b   Van Agtmael, M A ^c   Van De Laar, M A F J ^d   Van Der Poll, T ^e,f   Tak, P P ^g   Bijlsma, J W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f Centrum Voor Experimentele en Moleculaire Geneeskunde

^g NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; INFLUENZA VACCINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ASPERGILLOSIS; CANDIDIASIS; CLINICAL PRACTICE; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; EVIDENCE BASED MEDICINE; HISTOPLASMOSIS; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INFLUENZA; LISTERIOSIS; MYCOBACTERIOSIS; NOCARDIOSIS; OPPORTUNISTIC INFECTION; REVIEW; TUBERCULOSIS;

HUMANS; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINES; RISK FACTORS; TUMOR NECROSIS FACTORS;

EID: 33947708814     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Derksen RHWM, Bijlsma JWJ. De behandeling van chronische ontstekingsziekten met monoklonale antistoffen tegen tumornecrosisfactor: bijwerkingen, contra-indicaties en voorzorgen. Ned Tijdschr Geneeskd. 2002;146:1165-8.
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85.
3. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287-93.
4. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-55.
5. Bran C, Gomez i Prat J, Cayla JA, Garcia de Olalla P. Estudio de los factores asociados a la infeccion tuberculosa latente en inmigrantes menores de 35 anos. Enferm Infecc Microbiol Clin. 2006;24:322-5.
6. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986-92.
7. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl. 2005;74:35-9.
8. Hyrich KL. Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design. J Rheumatol Suppl. 2005;72:48-50.
9. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001:345:1098-104.
10. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis. 2004;39:1254-5.
11. Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother. 2001;2:75-84.
12. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403-12.
13. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368-76.
14. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven R van, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
15. Heijde D van der, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063-74.
16. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983-9.
17. Hamilton CD. Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum. 2003;48:2085-91.
18. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-alpha treatments. Rheumatology (Oxford). 2005;44:1205-6.
19. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis. 2005;64:1360-1.
20. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48:3013-22.
21. Hill PC, Brookes RH, Adetifa IM, Fox A, Jackson-Sillah D, Lugos MD, et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics. 2006;117:1542-8.
22. Kaufmann SH. New issues in tuberculosis. Ann Rheum Dis. 2004;63(Suppl 2):ii50-6.
23. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001;76:653-6.
24. Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718-22.
25. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003;42:617-21.
26. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-70.
27. Minnee RC, Stokkers P, Riemens SC, Hommes DW. Pneumocystis-pneumonie tijdens behandeling met infliximab voor actieve Crohn-colitis. Ned Tijdschr Geneeskd. 2005;149:2290-5.
28. True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol. 2002;29:1561-3.
29. Rijkeboer A, Voskuyl A, Agtmael M van. Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-α antagonist. Scand J Infect Dis. 2007;39:80-3.
30. Haerter G, Manfras BJ, Jong-Hesse Y de, Wilts H, Mertens T, Kern P, et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis. 2004;39:e88-94.
31. Vonkeman H, Napel C ten, Rasker H, Laar M van de. Disseminated primary varicella infection during infliximab treatment. J Rheumatol. 2004;31:2517-8.
32. Broeder AA den, Creemers MCW, Jong E de, Rooij DJRAM de, Fransen J, Hoogen FHJ van den. Identification of risk factors for surgical site infections and other complications in elective surgery in RA patients with special attention for anti-TNF: a large retrospective study. J Rheumatol. [ter perse].
33. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55:333-7.
34. Gluck T. Vaccinate your immunocompromised patients! Rheumatology (Oxford). 2006;45:9-10.
35. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65:191-4.
36. Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45:106-11.
37. Roukens AHE, Visser LG. Het risico van gele koorts voor reizigers. Ned Tijdschr Geneeskd. 2006;150:1815-20.
38. Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002;34:1369-78.